Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Novo Nordisk A/S : increased reported operating profit by 5% in the first nine months of 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2017 | 07:31am CET

Reported sales increased by 2% to DKK 83.7 billion (3% in local currencies)

Sales within diabetes and obesity care increased by 7% to DKK 69.7 billion (8% in local currencies).

  • Sales of Tresiba® increased by 117% to DKK 5.4 billion (118% in local currencies).
  • Sales of Victoza® increased by 15% to DKK 16.9 billion (15% in local currencies).
  • Sales of Saxenda® increased by 80% to DKK 1.9 billion (77% in local currencies)

Sales within biopharmaceuticals declined by 18% to DKK 14.0 billion (18% in local currencies), primarily reflecting an impact from the introduction of a generic version of the hormone replacement therapy product Vagifem® and from rebate adjustments for human growth hormone in Q1 2016, both in the USA, whereas sales within haemophilia were broadly unchanged.

Sales within International Operations increased by 3% in Danish kroner (5% in local currencies) driven by sales growth in all business regions. Sales within North America Operations were unchanged in both Danish kroner and local currencies, reflecting the non-recurring effects in biopharmaceuticals impacting growth negatively by 5 percentage points.

Operating profit increased by 5% reported in Danish kroner and by 6% in local currencies to DKK 38.9 billion. Net profit increased by 2% to DKK 29.9 billion. Diluted earnings per share increased by 5% to DKK 12.03.

In August, Novo Nordisk showed that the once-weekly GLP-1 semaglutide was superior to once-weekly dulaglutide on glucose control and weight loss in people with type 2 diabetes in the SUSTAIN 7 trial. In October, semaglutide received a positive 16-0 vote in favour of approval from an FDA Advisory Committee. 

In August, Novo Nordisk also obtained approval of the Victoza® label expansion for cardiovascular risk reduction in the USA, and in September the label expansion for the reduced risk of severe hypoglycaemia with Tresiba® was endorsed by CHMP in the EU. Also in September, Novo Nordisk obtained approval of the new fast-acting mealtime insulin Fiasp® in the USA. 

The financial outlook for 2017 has been updated and the sales growth measured in local currencies is now expected to be in the range of 2% to 3% compared with the previous range of 1% to 3%. A negative currency impact of 2 percentage points is now expected. Operating profit growth measured in local currencies is now expected to be in the range of 3% to 6% compared with the previous range of 1% to 5%. A negative currency impact of 3 percentage points is now expected. 

The preliminary outlook for 2018 in local currencies indicates low to mid single-digit growth in both sales and operating profit. Sales growth reported in Danish kroner is expected to be 3 percentage points lower than in local currencies, and reported operating profit growth is expected to be 4 percentage points lower. 

Lars Fruergaard Jørgensen, president and CEO: "We continue to deliver on our plans for 2017, and we are very pleased with the recent clinical and regulatory progress for our key products. We are currently preparing the global launch of semaglutide, which provides a unique opportunity to improve the treatment of people with type 2 diabetes."

Contacts for further information

Media:    
Katrine Sperling +45 3079 6718 [email protected]
Ken Inchausti (US) +1 267 809 7552 [email protected]
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 [email protected]
Hanna Ögren +45 3079 8519 [email protected]
Anders Mikkelsen +45 3079 4461 [email protected]
Christina Kjær +45 3079 3009 [email protected]
Kasper Veje (US) +1 609 235 8567 [email protected]

Company announcement No 83 / 2017





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK A/S
11/21 NOVO NORDISK A/S : Selects Emerson to Help Bring Medication to Market More Quick..
11/21 NOVO NORDISK A/S : Health Canada approves Victoza® as the first and only GLP-1 r..
11/21 NOVO NORDISK A/S : Highlights to be presented at Novo Nordisk's Capital Markets ..
11/21 NOVO NORDISK A/S : New US Study Reveals Key Reasons Why Millions of People With ..
11/20 NOVO NORDISK A/S : - Share repurchase programme
11/18 NOVO NORDISK A/S : FDA approves Roche potential haemophilia blockbuster
11/16 NOVO NORDISK A/S : "Diabetes 360" Survey Shows Patients Want More Than Medicine,..
11/16 NOVO NORDISK A/S : - Share repurchase programme
11/16 NOVO NORDISK A/S : World Diabetes Day free diabetes clinic opens
11/15 DIABETES COMMUNITY AWAKENS IMPORTANT : Hypoglycemia
More news
News from SeekingAlpha
11/21 Novo Nordisk to present business priorities and growth plans today
11/20 My 27 Stock Portfolio
11/17 NOVO NORDISK : Q3 2017 Results Show Strong Future Potential
11/14 NOVO NORDISK Q3 2017 : Wait For Better Re-Entry Point
11/06 Comments On Q3 Results For Merck, Pfizer, Bristol-Myers And Novo Nordisk
Financials ( DKK)
Sales 2017 112 B
EBIT 2017 49 295 M
Net income 2017 38 390 M
Finance 2017 18 595 M
Yield 2017 2,39%
P/E ratio 2017 21,01
P/E ratio 2018 19,73
EV / Sales 2017 5,52x
EV / Sales 2018 5,35x
Capitalization 639 B
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 310  DKK
Spread / Average Target -4,8%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S23.16%100 887
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550